The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | CodeBreak 300: patient-reported tolerability of sotorasib and panitumumab in mCRC
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, gives an overview of patient-reported tolerability findings from the Phase III CodeBreak 300 trial (NCT05198934) of sotorasib with panitumumab versus investigator’s choice of trifluridine/tipiracil or regorafenib in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). Patient-reported outcomes showed comparable side effect bother across all groups, supporting sotorasib and panitumumab as a potential standard of care. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role – Amgen; Bayer; GlaxoSmithKline; Janssen; Merck Serono; MSD Oncology; Rottapharm Biotech; SERVIER; Takeda
Research Funding – Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
Travel, Accommodations, Expenses – Merck Serono; Pierre Fabre
